Clinical Data, Inc. Plays Integral Role in MicroArray Quality Control (MAQC) Consortium Project; FDA-Led Initiative Assessing Reproducibility of Microarray Data Featured in September 2006 Edition of Nature Biotechnology.

NEWTON, Mass. -- Cogenics, a division of Clinical Data Inc. (NASDAQ: CLDA) and comprised of the combined companies of Genaissance Pharmaceuticals, Lark (US and UK), Icoria, and Genome Express of France, today joined with other participants of the MicroArray Quality Control (MAQC) Consortium in publishing the results of the FDA-led initiative to assess the precision, reproducibility and comparability of microarray gene expression data. Cogenics contribution was unique in the generation and analysis of multi-platform gene expression data and resulted in three publications in the September 2006 issue of Nature Biotechnology.

"The MAQC project represents a key step towards establishing the use of microarrays in the discovery, development and review of FDA-regulated products," said Robert Bondaryk, PhD, General Manager of Cogenics. "The success of these efforts distinguishes Cogenics from the few gene expression services providers focused on data production within an FDA-regulated environment. The ability to provide these services for a significant number of major companies is a testimony to Cogenics' years of experience, know-how and leadership position in this area."

The completion of the MAQC project represents a milestone toward FDA's "Critical Path Initiative," which identifies pharmacogenomics and toxicogenomics as key opportunities in advancing medical product development and personalized medicine. This project involved the combined efforts of government and academic laboratories, providers of RNA samples and gene expression platforms, and gene expression service providers. The aim of the MAQC project has been to establish quality metrics and guidelines for data analysis for the scientific community. This work has generated a large, publicly-available data set that demonstrates the reproducibility of gene expression data obtained from microarrays, and provides a resource to the larger scientific community to evaluate and assess the quality of their own data and procedures.

Bondaryk continued, "We are pleased to participate in the community-wide 'standardization' initiatives to advance the use of microarray data for research and regulatory submissions, including the current FDA-initiated project and other ongoing efforts with the NIEHS Toxicogenomics Research Consortium. We are very proud of our extensive experience with multiple gene expression profiling platforms and long history of performing complex gene expression studies for pharmaceutical and biotechnology companies, as well as for government and academic researchers in the life science community. The success of the MicroArray Quality Control Project ensures that these technologies will continue to play a critical role in biological research globally and in the new drug approval process."

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care. The Company, founded in 1972, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth(TM); Cogenics(TM); and Vital Diagnostics(TM). Clinical Data's Therapeutic Diagnostics(TM) division, PGxHealth, builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth plans to develop and introduce novel Therapeutic Diagnostics in some instances in combination with new and existing therapeutics. Clinical Data's Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005, and Genome Express SA, acquired in 2006. Cogenics provides a comprehensive range of molecular and pharmacogenomics services to pharmaceutical, biotech, academia, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. Clinical Data's Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l. This division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data currently employs a staff of over 430. The Company is headquartered in Newton, Massachusetts with operations in Texas, Connecticut, RTP - North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia. Furthermore, Clinical Data has numerous distribution, licensing, development and other collaborations with key partners.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005, 2006, and 2007 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com